🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruitingn/aAges 18 Years - anyAllThe First Affiliated Hospital with Nanjing Medica…
NCT05967949 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment. Exclusion Criteria: * (1) Patients with other types of lymphomas; (2) Pregnant women.
💊

What it tests

  • chidamide
📍

Where

1 site
Hematological Department, People's Hospital of Jiangsu Province
Nanjing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy